Join our Sales team as a Field Account Manager and play a key role in driving revenue growth and building long-term customer relationships across assigned accounts in your territory. By leading the commercial sales process, executing account plans and coordinating Technical Sales involvement, you will help customers adopt solutions that contribute to better health for more people.
Based in Italia, this field-based role involves more than 50% travel to engage directly with customers.

Please apply in English only.

Grow With Us – Your Responsibilities

Build and maintain strong, multi-level, long-term customer relationships to strengthen account engagement, satisfaction and retention and protect recurring revenue
Expand Sartorius’ share of wallet within assigned accounts through cross-selling and multi-product penetration in line with account plans and expected portfolio mix, increasing revenue per account
Lead the commercial stages of the sales cycle, including proposals, negotiations and commercial closure, while coordinating Technical Sales involvement for early-stage opportunity creation, technical validation and technical closure to increase win rates and solution adoption
Identify and develop growth opportunities within assigned accounts, leveraging Technical Sales for technical validation, trials and solution design to deepen stakeholder engagement, uncover new internal use cases and expand adoption of the Sartorius portfolio
Drive adoption of innovative and newly launched products by positioning their value, ensuring successful implementation and delivering NPI-related targets, including adoption rates and conversion from trials, to accelerate time to revenue
Integrate newly won customers into the assigned account base to ensure relationship continuity and expansion, capturing new use cases in the account plan to enable systematic account development and prevent value leakage after the sale
Use SFDC actively to maintain pipeline accuracy, document customer interactions and ensure accurate forecasting and data-driven territory steering, supporting effective prioritization and performance transparency

What Will Convince Us

Bachelor’s degree in Life Sciences, Engineering or a related field
3+ years of field sales experience in the life science or technical industry, managing mid-size or large accounts
Strong commercial acumen with proven negotiation, opportunity management and account planning skills
Confident communication skills and the ability to influence diverse decision-makers and effectively partner with Technical Sales to shape customer solutions
High proficiency in CRM (SFDC) for pipeline management, forecasting and data-driven sales steering
Self-driven and results-oriented approach, with the ability to coordinate cross-functional stakeholders to deliver account outcomes
Willingness to travel more than 50%, reflecting the role’s strong focus on external customers

About Sartorius

Sartorius is part of the solution in the fight against cancer, dementia, and many other diseases. Our technologies help translate scientific discoveries into real-world medicine faster, so that new therapeutics can reach patients worldwide.

We look for ambitious team players and creative minds, who want to contribute to this goal and advance their careers in a dynamic global environment.

Join our global team and become part of the solution. We are looking forward to receiving your application.
www.sartorius.com/careers

About the company

Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify's Take

What believers are saying

H1 2026 operational sales rose 7.7%, and management reaffirmed full-year guidance.
May 2026 bond refinancing lowered funding pressure before the €650 million maturity.
ElevateBio pilot validation and September 2026 ordering support Eveo sales conversion in 2027.

What critics are saying

Tariff refunds and customer compensation cut 2026 revenue by up to €35 million.
Lab Products grew only 5.3% operationally in H1 2026, lagging Bioprocess Solutions.
Delayed advanced-therapy orders from two customers shift revenue into 2027, hurting execution confidence.

What makes Sartorius unique

Eveo launches March 16, 2026, integrating cell therapy manufacturing and QC in one system.
Bioprocess Solutions dominates with high-recurring consumables and switching costs across biologics manufacturing.
Stedim Biotech integration gives Sartorius tighter control over single-use bioprocessing and global customer relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget

Company News

Yahoo Finance

Oct 23rd, 2026

Sartorius Stedim Biotech nine-month sales up 7.8% to $2.5B, full-year guidance confirmed

Sartorius Stedim Biotech reported nine-month sales growth of 7.8% in constant currencies, or 6.5% after tariff-related customer compensation. Sales reached €2.29 billion, driven by strong consumables and a recovering equipment business. Underlying EBITDA rose 4.8% to €716 million, with a margin of 31.3%. Underlying net profit climbed 9.4% to €350 million, and free cash flow jumped 58.5% to €264 million. Net debt stood at €2.14 billion, or 2.26 times underlying EBITDA. Americas growth lagged at 3.9% including tariff compensation, hurt by project delays in Advanced Therapies. The company confirmed full-year guidance: operational sales growth near the midpoint of 6% to 10% and an underlying EBITDA margin slightly above 31%.

Yahoo Finance

Jul 23rd, 2026

Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS

May 15th, 2026

Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG

May 6th, 2026

Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius